(MedPage Today) — First-line treatment with a recently approved targeted agent demonstrated durable efficacy in advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), results of the phase I Beamion LUNG-1 trial showed.
In 74 previously…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
